Lilly(US:LLY) Zhong Guo Xin Wen Wang·2025-11-05 14:36Core Insights - Crystal Technology's subsidiary Ailux has entered into a multi-target strategic collaboration and platform licensing agreement with Eli Lilly, valued at up to $345 million [2] - This partnership follows a previous $250 million agreement for AI small molecule drug collaboration, highlighting the ongoing relationship between the two companies [2] - The collaboration aims to accelerate the discovery and development of bispecific antibodies using Ailux's proprietary platform, showcasing the international recognition of its AI capabilities in drug development [2][3] Company Overview - Ailux, established by Crystal Technology in 2021, focuses on the development of large molecule drugs and has rapidly progressed in commercial outcomes over the past two years [3] - The platform integrates quantum physics, AI, and high-throughput wet lab capabilities to design high-potential antibody drugs targeting complex disease mechanisms [3] - Ailux has successfully served multiple top international pharmaceutical companies and validated its platform in several research projects [3] Market Potential - Antibodies are a core drug form that outperforms small molecules in terms of annual growth rate, blockbuster drug ratio, and clinical success rates [2] - The global drug market for antibodies is projected to grow from $288.4 billion in 2025 to $628.5 billion by 2035, indicating a continuous increase in market share [2]